Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PTP22 Double Nickase Plasmid (h): sc-416917-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PTP22 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- PTP22 Double Nickase Plasmid (h) and PTP22 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting PTPN22. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PTP22 Antibody (E-5): sc-393766
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PTP22 Double Nickase Plasmid (h) | sc-416917-NIC | 20 µg | $410.00 | |||
PTP22 Double Nickase Plasmid (h2) | sc-416917-NIC-2 | 20 µg | $410.00 |
PTPN22 encodes protein tyrosine phosphatase non-receptor type 22 (PTP22), a cytosolic phosphatase that attenuates signaling downstream of antigen receptors by dephosphorylating key kinases and adaptor proteins. In immune cells, PTP22 shapes activation thresholds and influences pathways linked to T cell receptor and B cell receptor signaling, including phosphorylation-dependent control of MAPK and NF-κB outputs. Genetic and functional studies have connected altered PTP22 activity to dysregulated immune tolerance and inflammatory signaling. As a result, PTPN22 is widely investigated in models of autoimmune susceptibility, immune cell differentiation, and signaling network rewiring.
PTP22 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the PTPN22 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within PTPN22. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt PTPN22 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of PTPN22-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.